LA JOLLA PHARMACEUTICAL CO Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 9 rows, 9 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-08-22: Reporting owner TANG KEVIN C; Form 4; Security Series C-1(2) Convertible Preferred Stock; Transaction U Disposition pursuant to a tender of shares in a change of control transaction.
- 2022-08-22: Reporting owner Hearne Michael S; Form 4; Security Series C-1 (2) Convertible Preferred Stock; Transaction U Disposition pursuant to a tender of shares in a change of control transaction.
- 2022-08-22: Reporting owner Hearne Michael S | TANG CAPITAL MANAGEMENT LLC | TANG KEVIN C | TANG CAPITAL PARTNERS LP; Form 4; Security Series C-1(2) Convertible Preferred Stock; Transaction U Disposition pursuant to a tender of shares in a change of control transaction.
- 2014-08-04: Reporting owner TANG CAPITAL PARTNERS LP | TANG CAPITAL MANAGEMENT LLC | TANG KEVIN C; Form 3; Security Series C-1(2) Convertible Preferred Stock; Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-08-22 | TANG KEVIN C Director, 10% Owner | 4 | Series C-1(2) Convertible Preferred Stock Derivative · Indirect · (m) | U Disposition pursuant to a tender of shares in a change of control transaction | −3,519 0 owned after | no price filed | 2022-08-24 | |
| 2022-08-22 | Hearne Michael S Officer (Chief Financial Officer) | 4 | Series C-1 (2) Convertible Preferred Stock Derivative · Indirect · (m) | U Disposition pursuant to a tender of shares in a change of control transaction | −3,519 0 owned after | no price filed | 2022-08-24 | |
| 2022-08-22 | Hearne Michael S | TANG CAPITAL MANAGEMENT LLC | TANG KEVIN C | TANG CAPITAL PARTNERS LP Officer | 10% Owner | Director, 10% Owner | 10% Owner | 4 | Series C-1(2) Convertible Preferred Stock Derivative · Indirect · By LP | U Disposition pursuant to a tender of shares in a change of control transaction | −3,519 0 owned after | no price filed | 2022-08-24 | |
| 2014-08-04 holding as of filing | TANG CAPITAL PARTNERS LP | TANG CAPITAL MANAGEMENT LLC | TANG KEVIN C 10% Owner | 10% Owner | 10% Owner | 3 | Series C-1(2) Convertible Preferred Stock Derivative · Indirect · By LP | Holding | no price filed | 2014-08-04 | ||
| 2011-05-09 | Gillespie Deirdre Director, Officer (President & CEO) | 4 | Series C-1 Convertible Preferred Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1 111 owned after | $595.00 | 2011-05-18 | |
| 2010-05-26 | SLOAN GAIL A Officer (Chief Financial Officer) | 4 | Series C-1 Convertible Preferred Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22 22 owned after | $1,000.00 | 2010-05-28 | |
| 2010-05-26 | Gillespie Deirdre Director, Officer (President & CEO) | 4 | Series C-1 Convertible Preferred Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +104 104 owned after | $1,000.00 | 2010-05-28 | |
| 2009-03-27 | BIOMARIN PHARMACEUTICAL INC 10% Owner | 4 | Series B-1 Convertible Preferred Stock Derivative · Direct | C Conversion of derivative security | −339,104 0 owned after | $0.00 | 2009-06-19 | |
| 2009-01-30 holding as of filing | BIOMARIN PHARMACEUTICAL INC 10% Owner | 3 | Series B-1 Convertible Preferred Stock Derivative · Direct | Holding | no price filed | 2009-01-30 |